The positive effect of the pandemic: Virtualization and Advanced Analytics for the next-generation clinical trials

Sponsored by: Exom Group Srl.

Focused on:

  • Covid 19
  • Clinical
  • Trials
  • Research

Date: 23 November


Time: 2PM London / 3pm CET

How digital technologies modernize clinical trials and how patients, investigators and sponsors will benefit from this change.

Digital technologies have been used in clinical studies for years. So far, however, they have been used very hesitantly by sponsors, study centers and CROs. Authorities have also been very hesitant to approve their use.
The Covid-19 pandemic, however, has changed this attitude. Innovative Digital technologies, such as telemedicine or remote informed consent and site monitoring, rapidly found their way into clinical trials, and regulatory authorities, sponsors, investigators and patients are ready to break new grounds.

The path Exom has taken with its customers since its founding, namely to conduct clinical trials using innovative technologies and advanced analytics, has proven to be the right one.

In this webinar we will show, from the perspective of a sponsor and a CRO, the following points:

• How studies can be conducted virtually
• How advanced analytics and machine learning can be used in different areas of study execution
• How study stakeholders can benefit from these innovations

Register now to save your space!

Presented by

Nicola Bottone,

Nicola Bottone holds summa cum laude the Master's Degree in Computer Engineering. Later has obtained the Master in European Business, General Management, at the ESCP Europe Business School, with merit. Furthermore, he has earned an MBA in International Management. Nicola worked as a business consultant for Reply, analyzing the e-health market and the main players involved and then for KPMG, carrying out the definition of the energy market for the BRIS.

Nicola has been working for Reply since 2012 and is mainly dedicated to define new business models and evolutions in the offer, as well as structuring the products and services in the Telemedicine field, exploiting the new technologies and potential offered by the IoT/IoMT (Internet of Medical Things) and the Cloud. He currently serves mainly as Product Manager for the Telemedicine solution and he is the point of contact between the various companies in the group and accounts for the main business partners. Nicola acts as “pivot” between three main areas: Strategical, Commercial and Technological. Starting from August 2018 Nicola leads the R&D EU Funded group also. Starting from January 2020 Nicola covers the role of Business Unit Manager also.

Among the most innovative propositions developed, Nicola personally led those on IoMT Corporate Welfare, “Presa in Carico”, Blockchain in Healthcare, Rare Diseases, Intelligent Clinical Trial, and Patient Support Program.

Marco Villa,

Clinical Operations Director

Marco Villa is a professional in clinical research with an experience of over 15-years, working both in pharmaceutical companies and CRO business. After the university degree in pharmaceutical chemistry and technologies, he started a career as CRA in 2004. Three years later Marco became a project manager, a role that he covered for nine years, working on local and international studies, both interventional and non-interventional, in several therapeutic areas, including oncology, cardiology, respiratory and infectious diseases. He managed the largest trial ever done in acute pulmonary embolism.

His primary duty at Exom is to support the company to drive the innovation of clinical research through a risk-based and data-driven management of clinical studies, utilizing the most innovative technologies and advanced analytics.

Patrick McManus,

MSc – Chief Development Officer at Exom Group

Holding a Master of Science in Clinical Research from the Danube University Krems and a diploma in Business Administration and Computational Sciences from the Academy of Public and Business Administration in Munich Patrick is bringing more than 12 years of experience in Business Development in the CRO business. During his career, he gained a solid understanding of all aspects of clinical trials and deep knowledge in Business Development. He held several leading positions in the area of Business Development in mid-size CROs.

Key Learning Objectives

  • How studies can be conducted virtually
  • How advanced analytics and machine learning can be used in different areas of study execution
  • How study stakeholders can benefit from these innovations


  • VP (Global) Clinical Operations
  • Heads of (Global) Clinical Operations
  • VP Research & Development
  • Heads of Research & Development
  • VP of Drug Development
  • Heads of Drug Development
  • Chief Medical Officers
  • C-Levels
  • Project Managers
  • VPs of Procurement
  • Heads of Procurement